Categories
Change Password!
Reset Password!
Given its cost-effective and safety, the use of empirical Bismuth-Based
Quadruple therapy can be considered in Helicobacter pylori eradication.
As compared to tailored therapy, the use of empirical
bismuth quadruple therapy (BQT) for 10 days was found to be safe, effective and
cost effective option as per the clarithromycin resistance (CR) test for the
eradication of Helicobacter pylori infection, a study in Digestive Diseases and
Sciences concluded.
To distinguish between the efficacy of standard triple
treatment (STT) and empirical BQT and; determine the cost-effectiveness of
tailored treatment according to CR test outcomes, Young Woon Chang et al,
considered 490 patients with H. pylori infection having chronic gastritis or
stomach ulcer.
Out of these patients, 292 undertook CR testing.
The patients on STT for a week and BQT for 10 days based on their CR test
results were assigned to the tailored group (282 patients). The rest of the
patients were in the empirical group
(198 patients) who were subjected to BQT for 10 days.
About 32.2% patients (94 patients out of 292 patients) had a CR-positive rate in the tailored group. The eradication rates as per intention-to-treat analysis and per-protocol analysis has been represented in the following table:
Patients
in the empirical group had lower frequency of adverse events as compared to
tailored group (35.1% versus 52.7%, P < 0.001). Also, lower total per capita
medical costs was beared by empirical group patients ($406.50 versus $503.50).
Digestive Diseases and Sciences
Cost-Effectiveness of Empirical Bismuth-Based Quadruple Therapy and Tailored Therapy After Clarithromycin Resistance Tests for Helicobacter pylori Eradication
Young Woon Chang et al.
Comments (0)